ملخص
A patient being treated for sickle cell disease with hydroxyurea (1 g/d) conceived, and drug treatment was discontinued at nine weeks gestational age. The pregnancy and delivery were complicated by vaso-oclusive crises. A healthy male infant was born at 39 weeks with no evidence of congenital malformations. A literature review, including this case, suggests that the risk of hydroxyurea exposure during in pregnancy may have been overestimated. Further studies are required to determine its safety in pregnancy.
اللغة الأصلية | الإنجليزيّة |
---|---|
الصفحات (من إلى) | 148-150 |
عدد الصفحات | 3 |
دورية | American Journal of Hematology |
مستوى الصوت | 60 |
رقم الإصدار | 2 |
المعرِّفات الرقمية للأشياء | |
حالة النشر | نُشِر - 1999 |
منشور خارجيًا | نعم |